NDC 0023-3616

LATISSE

Bimatoprost

LATISSE is a Ophthalmic Solution/ Drops in the Human Prescription Drug category. It is labeled and distributed by Allergan, Inc.. The primary component is Bimatoprost.

Product ID0023-3616_476e4325-4bd9-4086-be6b-b9044c57e480
NDC0023-3616
Product TypeHuman Prescription Drug
Proprietary NameLATISSE
Generic NameBimatoprost
Dosage FormSolution/ Drops
Route of AdministrationOPHTHALMIC
Marketing Start Date2009-01-26
Marketing CategoryNDA / NDA
Application NumberNDA022369
Labeler NameAllergan, Inc.
Substance NameBIMATOPROST
Active Ingredient Strength0 mg/mL
Pharm ClassesProstaglandin Analog [EPC],Prostaglandins [CS]
NDC Exclude FlagN
Listing Certified Through2021-12-31

Packaging

NDC 0023-3616-03

1 BOTTLE, DROPPER in 1 CARTON (0023-3616-03) > 3 mL in 1 BOTTLE, DROPPER
Marketing Start Date2009-01-26
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 0023-3616-70 [00023361670]

LATISSE SOLUTION/ DROPS
Marketing CategoryNDA
Application NumberNDA022369
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2009-01-26

NDC 0023-3616-16 [00023361616]

LATISSE SOLUTION/ DROPS
Marketing CategoryNDA
Application NumberNDA022369
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2009-01-26

NDC 0023-3616-05 [00023361605]

LATISSE SOLUTION/ DROPS
Marketing CategoryNDA
Application NumberNDA022369
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2009-01-26

NDC 0023-3616-80 [00023361680]

LATISSE SOLUTION/ DROPS
Marketing CategoryNDA
Application NumberNDA022369
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2009-01-26

NDC 0023-3616-15 [00023361615]

LATISSE SOLUTION/ DROPS
Marketing CategoryNDA
Application NumberNDA022369
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2012-08-02
Marketing End Date2013-01-07

NDC 0023-3616-04 [00023361604]

LATISSE SOLUTION/ DROPS
Marketing CategoryNDA
Application NumberNDA022369
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2009-01-26

NDC 0023-3616-03 [00023361603]

LATISSE SOLUTION/ DROPS
Marketing CategoryNDA
Application NumberNDA022369
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2009-01-26

NDC 0023-3616-81 [00023361681]

LATISSE SOLUTION/ DROPS
Marketing CategoryNDA
Application NumberNDA022369
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2009-01-26

NDC 0023-3616-71 [00023361671]

LATISSE SOLUTION/ DROPS
Marketing CategoryNDA
Application NumberNDA022369
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2009-01-26

Drug Details

Active Ingredients

IngredientStrength
BIMATOPROST.3 mg/mL

OpenFDA Data

SPL SET ID:34f83d9d-2c64-463e-8a90-9a460fedfead
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 1041497
  • 1041495
  • PHarm Class EPC
  • Prostaglandin Analog [EPC]
  • NUI Code
  • N0000175454
  • N0000007706
  • Pharmacological Class

    • Prostaglandin Analog [EPC]
    • Prostaglandins [Chemical/Ingredient]
    • Prostaglandins [CS]
    • Prostaglandin Analog [EPC]
    • Prostaglandins [CS]

    NDC Crossover Matching brand name "LATISSE" or generic name "Bimatoprost"

    NDCBrand NameGeneric Name
    0023-3616LATISSEbimatoprost
    0781-6206BimatoprostBimatoprost
    42571-128BIMATOPROSTBIMATOPROST
    50383-908BimatoprostBimatoprost
    50383-912BimatoprostBimatoprost
    57297-429bimatoprostbimatoprost
    60505-0583BimatoprostBimatoprost
    62332-507BimatoprostBimatoprost
    62332-511bimatoprostbimatoprost
    65862-802BimatoprostBimatoprost
    68083-295BimatoprostBimatoprost
    68083-296BimatoprostBimatoprost
    68083-439BimatoprostBimatoprost
    0023-9652DURYSTAbimatoprost
    0023-3205LUMIGANbimatoprost

    Trademark Results [LATISSE]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    LATISSE
    LATISSE
    77921801 not registered Dead/Abandoned
    Wet Enterprises, Inc.
    2010-01-27
    LATISSE
    LATISSE
    77449970 3620623 Live/Registered
    Allergan, Inc.
    2008-04-16

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.